Lead Product(s) : Beinaglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Yishengtai (benaglutide) is a fully human GLP-1 drug, which mainly used for weight loss effect in the clinical use of type 2 diabetes and comprehensive benefits for overweight and mechanisms such as enhancing satiety, delaying gastric emptying.
Product Name : Yishengtai
Product Type : Peptide
Upfront Cash : Inapplicable
March 15, 2022
Lead Product(s) : Beinaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Beinaglutide
Therapeutic Area : Endocrinology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Yishengtai (benaglutide) is a fully human GLP-1 drug, which mainly used for weight loss effect in the clinical use of type 2 diabetes and comprehensive benefits for overweight and mechanisms such as enhancing satiety, delaying gastric emptying.
Product Name : Yishengtai
Product Type : Peptide
Upfront Cash : Inapplicable
August 06, 2021
Lead Product(s) : Beinaglutide
Therapeutic Area : Endocrinology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable